• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Oxygen Biotherapeutics relocating R&D function to North Carolina

Oxygen Biotherapeutics relocating R&D function to North Carolina

August 29, 2012
CenterWatch Staff

Oxygen Biotherapeutics, a Morrisville, N.C.-based developer of medical and cosmetic products that efficiently deliver oxygen to tissues in the body, is searching for laboratory space in the Research Triangle Park region of North Carolina.

Beginning in September, Oxygen Biotherapeutics will be consolidating its operations and relocating its research and development function from Costa Mesa, Calif., to North Carolina. The company has already successfully subleased its Costa Mesa facility at terms that made the transition cost effective.

“North Carolina has the business climate, facilities and creative talent we need to help push our programs forward,” said Michael Jebsen, president and CFO, Oxygen Biotherapeutics. “Relocating R&D to North Carolina has been under consideration for quite some time, however, the recession strongly impacted the real estate market in southern California thereby preventing us from subletting the facility and making the transition sooner. We are excited about bringing this important function closer to our headquarters.”

Oxygen Biotherapeutics has engaged commercial real estate brokers to identify a new laboratory location. Three positions in California were eliminated due to the relocation and the company expects to replace these vacancies when the new facility is established. Current R&D activities allow for this transition period since most development work has been completed for the existing programs and all of the manufacturing of the company’s perfluorocarbon-based products—primarily Oxycyte and Dermacyte—is done by contract manufacturers.

“The foundation of this company was built primarily on research that came out of our Costa Mesa lab, and we wish to thank all our California-based employees for their efforts over the years,” added Jebsen. “They have given us novel perfluorocarbon-based products and it is now our challenge to move them through the clinical stages to commercialization.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing